Abstract
Relapsed or refractory lymphoma is commonly treated with combination chemoimmunotherapy and cellular immunotherapy. Modest response rates and associated toxicities are obstacles to achieving durable remission using traditional cytotoxic chemotherapy, especially in frail patients with advanced disease. Antibody drug conjugates represent a new class of novel targeted agents with significant improvement in therapeutic efficacy in the treatment of lymphomas. Several of these agents, which offer improved targeting, greater potency, and better therapeutic index over traditional chemotherapy, are changing the treatment landscape for lymphomas and other hematological malignancies. Despite the therapeutic potential of these agents, the delivery and release of cytotoxic agents to malignant cells through the combination of a monoclonal antibody, payload, and linker represents a complex design challenge. This article reviews the clinical data on currently available antibody drug conjugates and the ongoing development of novel antibody drug conjugates. Antibody drug conjugates constitute an important armamentarium for treatment of lymphomas and their evolving roles in the treatment spectrum are discussed.
Recommended Citation
Hashmi, Hamza; Darwin, Alicia; and Nishihori, Taiga
(2023)
"Therapeutic roles of antibody drug conjugates (ADCs) in relapsed/refractory lymphomas,"
Hematology/Oncology and Stem Cell Therapy: Vol. 16
:
Iss.
1
, Article 2.
Available at: https://doi.org/10.1016/j.hemonc.2021.07.002
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.
Included in
Cancer Biology Commons, Hematology Commons, Oncology Commons
